Clinical Trial: Long Term Safety Assessment of SER120 in Patients With Nocturia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Stu

Brief Summary: The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.

Detailed Summary:
Sponsor: Serenity Pharmaceuticals, Inc.

Current Primary Outcome: safety evaluation of SER120 in terms of laboratory and clinical assessments [ Time Frame: 11 month study ]

Original Primary Outcome: safety evaluation of SER120 in terms of laboratory and clinical assessments

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Serenity Pharmaceuticals, Inc.

Dates:
Date Received: September 18, 2009
Date Started: August 2009
Date Completion:
Last Updated: January 27, 2014
Last Verified: January 2014